Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 42
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Vaccine-induced neutralizing antibodies bind to the H protein of a historical measles virus.
Zemella A, Beer K, Ramm F, Wenzel D, Düx A, Merkel K, Calvignac-Spencer S, Stern D, Dorner MB, Dorner BG, Widulin N, Schnalke T, Walter C, Wolbert A, Schmid BG, Mankertz A, Santibanez S. Zemella A, et al. Int J Med Microbiol. 2024 Jan 20;314:151607. doi: 10.1016/j.ijmm.2024.151607. Online ahead of print. Int J Med Microbiol. 2024. PMID: 38367508
Therapeutic mitigation of measles-like immune amnesia and exacerbated disease after prior respiratory virus infections in ferrets.
Cox RM, Wolf JD, Lieberman NA, Lieber CM, Kang HJ, Sticher ZM, Yoon JJ, Andrews MK, Govindarajan M, Krueger RE, Sobolik EB, Natchus MG, Gewirtz AT, deSwart RL, Kolykhalov AA, Hekmatyar K, Sakamoto K, Greninger AL, Plemper RK. Cox RM, et al. Nat Commun. 2024 Feb 8;15(1):1189. doi: 10.1038/s41467-024-45418-5. Nat Commun. 2024. PMID: 38331906 Free PMC article.
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ, Nace RA, Balakrishnan B, Zhang L, Packiriswamy N, Singh G, Warang P, Mena I, Narjari R, Vandergaast R, Peng K-W, García-Sastre A, Schotsaert M, Russell SJ. Muñoz-Alía MÁ, et al. mBio. 2024 Feb 14;15(2):e0292823. doi: 10.1128/mbio.02928-23. Epub 2024 Jan 9. mBio. 2024. PMID: 38193729 Free PMC article.
Serological investigation of vaccine-induced antibodies for measles, rubella, and yellow fever viruses in children vertically exposed to Zika virus or with down syndrome.
Familiar-Macedo D, Dias HG, Carvalho FR, Pauvolid-Corrêa A, da Silveira MN, de Oliveira MC, Gonçalves RCF, Vianna RAO, Cardoso CAA, Boy da Silva RT, Baumblatt AP, de-Oliveira-Pinto LM. Familiar-Macedo D, et al. Front Pediatr. 2023 Dec 14;11:1250059. doi: 10.3389/fped.2023.1250059. eCollection 2023. Front Pediatr. 2023. PMID: 38155740 Free PMC article.
Prenatal Exposure to Poly- and Perfluoroalkyl Substances (2009-2014) and Vaccine Antibody Titers of Measles, Mumps, Rubella, and Varicella in Children Four to Eight Years Old from the Healthy Start Cohort.
Zell-Baran LM, Dabelea D, Norris JM, Glueck DH, Adgate JL, Brown JM, Harrall KK, Calafat AM, Starling AP. Zell-Baran LM, et al. Environ Health Perspect. 2023 Dec;131(12):127018. doi: 10.1289/EHP12863. Epub 2023 Dec 26. Environ Health Perspect. 2023. PMID: 38147368 Free PMC article.
Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
Park SI, Park S, Lee K, Kwak HW, Kim YK, Park HJ, Bang YJ, Kim JY, Kim D, Seo KW, Lee SJ, Kim H, Kim Y, Kim DH, Park HJ, Jung SY, Ga E, Hwang J, Na W, Hong SH, Lee SM, Nam JH. Park SI, et al. Vaccine. 2024 Jan 12;42(2):69-74. doi: 10.1016/j.vaccine.2023.12.011. Epub 2023 Dec 14. Vaccine. 2024. PMID: 38097457
A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.
Thuluva S, Gunneri S, Turaga K, Mogulla RR, Yerroju V, Peta K, Suneetha PV, Matur RV. Thuluva S, et al. Contemp Clin Trials Commun. 2023 Nov 22;36:101232. doi: 10.1016/j.conctc.2023.101232. eCollection 2023 Dec. Contemp Clin Trials Commun. 2023. PMID: 38058513 Free PMC article.
Immunity to measles in COVID-19 era.
Ferrari C, Somma G, Coppeta L. Ferrari C, et al. Hum Vaccin Immunother. 2023 Dec 15;19(3):2274724. doi: 10.1080/21645515.2023.2274724. Epub 2023 Nov 3. Hum Vaccin Immunother. 2023. PMID: 37922407 Free PMC article. No abstract available.
Corrigendum to "Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants" [Vaccine 41(11) (2023) 1892-1901].
Kwak HW, Park HJ, Jung SY, Oh EY, Park SI, Kim Y, Park HJ, Park S, Kim YJ, Ko HL, Lee JA, Won H, Hwang YH, Kim SY, Kim SE, Bae SE, Yoon M, Kim JO, Song M, Lee SJ, Seo KW, Lee K, Kim D, Kim H, Lee SM, Hong SH, Nam JH. Kwak HW, et al. Vaccine. 2023 Nov 13;41(47):7033. doi: 10.1016/j.vaccine.2023.10.033. Epub 2023 Oct 19. Vaccine. 2023. PMID: 37863670 No abstract available.
Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine, and measles-mumps-rubella vaccine to healthy infants aged 18 months in China.
Xu Y, Chen H, Wang B, Zhu X, Luo L, Wang S, Xiao Y, Wang H, Ma R, Liu S, Yan L, Li X, Chen D, Su Y, Chai Y, Fu J, Mao X, Cao J, Sun P, Tang F, Sun X, Wang Z, Yang X. Xu Y, et al. Int J Infect Dis. 2023 Dec;137:9-15. doi: 10.1016/j.ijid.2023.10.006. Epub 2023 Oct 11. Int J Infect Dis. 2023. PMID: 37832931 Free article. Clinical Trial.